Nanoviricides News

Nanoviricides | 10-Q: Quarterly report

SEC announcement01:24 · Announcements

NYSE American New 52-Week Highs And Lows

New Highs 5 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Actinium Pharmaceuticals ATNM 9.99 307,312 Am

Dow JonesMay 14 23:20

NanoViricides Unveils New Data Showing Lead Drug Asset's Strong Activity Against RSV | NYSE-A:NNVC

Proactive InvestorsMay 14 16:30

NanoViricides CEO Discusses NV-387's Broad-spectrum Antiviral Potential | NYSE-A:NNVC

Proactive InvestorsMay 13 23:13

NanoViricides to Showcase Lead Drug Asset's Progress at EF Hutton Annual Global Conference | NYSE-A:NNVC

Proactive InvestorsMay 10 16:58

The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...

① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.

cls.cnMay 10 16:52

NanoViricides Reports Research With NV-387 Showing Promising Results Against Multiple Viruses | NYSE-A:NNVC

Proactive InvestorsMay 9 20:25

NanoViricides Reports Breakthrough in Treating Airborne Viruses, Boosting Lifespan in Infected Mice

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against or

BenzingaMay 8 18:37

NanoViricides Says Lead Asset Shows Antiviral Activity Against Smallpox and Mpox | NYSE-A:NNVC

Proactive InvestorsMay 8 17:05

NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers

Seeking AlphaMay 7 22:01

12 Health Care Stocks Moving In Monday's Intraday Session

GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc

BenzingaMay 7 00:31

NanoViricides' Broad-Spectrum Antiviral NV-387 Offers Protection Against Influenza A and Bird Flu

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses

BenzingaMay 6 18:33

NanoViricides Drug Asset Shows 'superior Antiviral Effects' Against Influenza A | NYSE-A:NNVC

Proactive InvestorsMay 6 17:16

NanoViricides Reports That The Phase I NV-387 Clinical Trial Is Completed Successfully And Data Lock Is Expected Soon

NanoViricides Reports That The Phase I NV-387 Clinical Trial Is Completed Successfully And Data Lock Is Expected Soon

BenzingaApr 30 18:34

NanoViricides Completes Phase 1 Trial of Lead Asset NV-387 | NYSE-A:NNVC

Proactive InvestorsApr 30 17:08

NanoViricides Restructures Agreements to Alleviate Financial Stress

TipRanksFeb 17 06:03

EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target

EF Hutton analyst Tim Moore reiterates Nanoviricides (AMEX:NNVC) with a Buy and maintains $6.5 price target.

BenzingaFeb 16 20:14

Nanoviricides Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/16/2024 470.18% EF Hutton → $6.5 Reiterates Buy → Buy 06/01/2023 360.53% EF Hutton → $5.25 Assumes → Bu

BenzingaFeb 16 20:13

Nanoviricides Q2 EPS $(0.18) Down From $(0.15) YoY; As Of December 31, 2023, We Had Cash And Cash Equivalent Current Assets Balance Of Approximately $5.31M. Additional Agreements Have Resulted In A Further Approximately $2.5M Available Cash

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) per share from the same period last year.

BenzingaFeb 15 19:44

NanoViricides GAAP EPS of -$0.18

Seeking AlphaFeb 15 19:38